OneChart vs Vero Scribe (2026)

AI Health Index verifiedAugust 4, 2026
Verdict

Two small Canadian scribes serving the same clinics, separated mainly by how much each publishes. OneChart is a compact product with unusually wide clinical setting coverage for a team of its size, which suggests the note generation is general rather than tuned to one visit shape. Vero is the more developed commercial offering, with a complete self serve ladder, enumerated note types spanning consults, referrals and discharge summaries, evidence search and code lookup in one product, and compliance claimed across both the Canadian and United States regimes with a typed certification. For a clinic that wants to start this afternoon and know what it costs, Vero publishes more of what a buyer needs. Neither publishes an accuracy figure or a study, so run both on your own visits before committing.

The case for OneChart
  • It is a scribe rather than a record system, so a Canadian practice keeps what it runs and adds documentation on top.
  • The breadth of clinical settings it reaches is unusual for its size, suggesting note generation is genuinely general rather than tuned to one visit type.
  • A small focused product means a narrow surface to evaluate, which suits a clinic without an IT function.
The case for Vero Scribe
  • The commercial ladder is complete and self serve, published rather than quoted, with a trial that converts into a stated plan.
  • Note types are enumerated properly across consults, referrals and discharge summaries, with evidence search and code lookup in the same product.
  • Compliance is claimed across both the Canadian and United States regimes with a named and typed certification and a published retention position.

This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. OneChart and Vero Scribe are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded

At a Glance

Plain facts

Fact OneChart Vero Scribe
Primary category Ambient Scribes Ambient Scribes
Founded 2024 2020
Headquarters Hamilton, Ontario, Canada Toronto, Ontario, Canada
Website onechart.ai veroscribe.com
Attribute Matrix

Side by Side

Axis
O
OneChart
V
Vero Scribe
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Model Supply Chain Disclosure
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
AI Liability and Recourse
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage
Citable Summaries

Each record in one paragraph

Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.

OneChart

The AI Health Index awards OneChart its top capability grade on AI Centrality, Commercial Transparency and Setting and Specialty Coverage. Set against Vero Scribe, OneChart grades higher on EHR and Interoperability Depth and Setting and Specialty Coverage. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.

Source: AI Health Index, August 2026

Vero Scribe

The AI Health Index awards Vero Scribe its top capability grade on AI Centrality and Commercial Transparency. Set against OneChart, Vero Scribe grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.

Source: AI Health Index, August 2026

FAQ

Questions buyers ask

Should we choose OneChart or Vero Scribe?

On the axes where the AI Health Index separates them, OneChart grades higher on EHR and Interoperability Depth and Setting and Specialty Coverage, and Vero Scribe grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Vero Scribe leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.

Where do OneChart and Vero Scribe differ most?

The widest separation the AI Health Index records between OneChart and Vero Scribe is on Model Supply Chain Disclosure, where OneChart grades D and Vero Scribe grades B. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.

Where do OneChart and Vero Scribe grade the same?

The AI Health Index grades OneChart and Vero Scribe the same on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.

What have OneChart and Vero Scribe not disclosed?

At the last review, at least one of OneChart and Vero Scribe published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Ambient Scribes page.

Disclosure

Neither vendor publishes an accuracy figure, model card or evaluation methodology, and neither publishes a study or named deployment, so the diligence burden sits with the buyer on both sides. Vero describes no review gate, sign off step, confidence threshold or edit burden figure, which is notable for a self serve product where the clinician is the only control. For any dual regime claim, establish which entity holds the data and where processing occurs, because asserting compliance with two frameworks is not the same as demonstrating residency in each.